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A novel protocol for the one-pot borylation/
Suzuki reaction provides easy access to
hinge-binding groups for kinase inhibitors†
A. Hooper, A. Zambon‡ and C. J. Springer*‡
The one-pot borylation/Suzuki reaction is a very efficient means of accessing cross-coupling products of
two aryl-halide partners that generally requires the use of specific catalysts or ligands and/or relatively
long reaction times. This new microwave-assisted method provides a quick one-pot borylation/Suzuki
reaction protocol that we applied to the synthesis of various bi- or poly-aryl scaffolds, including a variety
of aryl and heteroaryl ring systems and the core frameworks of kinase inhibitors vemurafenib and
GDC-0879.
Introduction
Kinases are key functional proteins that regulate signal trans-
duction pathways in cells by catalyzing phosphorylation of
serine, threonine, or tyrosine residues. Deregulation of protein
kinases is implicated in many diseases including cancer, dia-
betes, and inflammation: as a consequence kinases have been
major targets for recent small molecule drug development.1–3
A common feature of most kinase inhibitors is the presence
of a hinge-binding moiety,4 a group that is able to form hydro-
gen bonds to the cleft between N- and C-lobes of the kinase
known as the hinge region.4 Typically, a hinge-binding struc-
ture consists of a hetero-aromatic group containing hydrogen
bond donors and/or acceptors in either a mono- or bi-dentate
fashion. This mode of binding mimics that of the adenosine
ring of the natural kinase ligand, ATP.
The palladium-catalysed Suzuki–Miyaura reaction, which
couples aryl halide and aryl boronic species for the formation
of new C–C bonds,5–8 is particularly suited to access hinge
binding fragments thanks to its tolerance of functional groups
and mild reaction conditions. Furthermore, extensive literature
describes a wide range of experimental procedures.9,10
Despite its wide scope, the Suzuki–Miyaura cross-coupling
reaction has a number of limitations such as lack of avail-
ability, high expense and instability of certain boronic species.
In order to circumvent these issues, Miyaura explored the use
of bis(pinocolato)diboron as the boronic acid equivalent in a
one-pot borylation/Suzuki reaction, which eliminates the need
to isolate the boronic intermediate. Despite subsequent
improvements to the methodology,11–15 current one-pot boryl-
ation/Suzuki protocols require double loading of specific cata-
lysts, use of additional ligands or relatively long reaction
times, and their scope is generally limited to one specific
scaffold.16–18
Our aim was to develop a robust one-pot borylation/Suzuki
protocol that employs one single loading of catalyst with no
need for additional ligands and to use it to access a small
panel of putative hinge binding fragments, which were then
profiled for kinase selectivity.
Results and discussion
As a model reaction for the optimisation of the one-pot proto-
col, we selected the coupling of 5-bromoindanone 1a and
3-bromopyridine 3a to give 3-pyridinylindenone 4a, mediated
by the formation of pinacolate boronic ester 2a. We reasoned
that the structure of 4a could act as a basic scaffold for a
kinase inhibitor, with the pyridine group acting as hinge
binder and the indanone elaborating into the ATP binding
pocket. Variation of this basic structure would then allow us to
access a panel of compounds with potential kinase activity.
The original borylation conditions, developed by Miyaura11
were assessed utilising Pd(dppf)Cl2 as the catalytic species and
KOAc as the base. Although this yields the boronic ester 2a
with 100% conversion, addition of 3-bromopyridine 3a, along
with catalyst and base did not yield 4a (Table 1, entry 1). Pd-
(PPh3)4 as catalyst was assessed for the Suzuki step but again
4a was not formed (entry 2). However, the borylation reaction
time could be shortened to 1 hour at 120 °C under microwave
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irradiation resulting in the formation of intermediate 2a. This
is a significant time reduction from 18 h needed at 80 °C
using both catalytic species (entries 3 and 4). From this point,
only tetrakis(triphenylphosphine)palladium(0) as catalyst was
utilized to avoid a mixture of catalytic species as this was
deemed most suitable due to its wide use and cheaper cost.
To identify the best reaction conditions to access 4a for a
one pot reaction, we postulated a bicyclic mechanism merging
the catalytic cycles 1 and 2 elucidated by Miyaura and Suzuki
for the borylation and coupling steps respectively,11,19 as out-
lined in Fig. 1. Cycle 1 is a typical borylation cycle with oxi-
dative–addition of the first halide to the catalytic species,
oxidising the palladium species from the neutral state of the
Pd(PPh3)4 to the Pd(II) species. Base1 then displaces the halide
within the catalytic complex, activating it for the subsequent
transmetallation step with bis(pinocolato)diboron.11,19 A final
reductive–elimination step recovers the Pd(0) catalytic species
and completes cycle 1, releasing the aryl-boronic species; at
this stage the reactions carried out in entries 1–4 stalled.
Similarly, catalytic cycle 2 is initiated by oxidative addition
of the second halide to the catalyst and the displacement of
the halide by Base2 followed by addition of the aryl boronate
to form the biaryl-substituted palladium species. Complexa-
tion of a base to the aryl boronate is essential at this stage in
order to accelerate the transmetallation step20 by forming a
more reactive boronate to interact with the palladium species21
and facilitate an intramolecular transmetallation.22 We postu-
lated that a stronger base is required at this step in cycle 2
than the one needed in cycle 1, which only has the role to dis-
place the halide from the first palladium species.
We then applied a change of base to our model system,
introducing sodium carbonate as second base after the for-
mation of intermediate 2a, and pleasingly the pyridinylinde-
none product 4a is formed with 100% conversion (entry 5). As
a further confirmation of the reaction mechanism, the intro-
duction of sodium carbonate in the borylation step affords
only the homocoupling product (entry 6).
Once the optimal base/catalyst system was identified, we
worked to eliminate the second catalyst loading and decrease
the reaction times. In these optimised conditions, 100% con-
version to product 4a was obtained (entry 7) using a single
initial loading of Pd(PPh3)4, with 45 minutes at 120 °C under
microwave irradiation for the borylation step, followed by
addition of 3a and Na2CO3 with further heating to 120 °C for
30 min in the Suzuki step.
Next, we applied this optimised protocol to the synthesis of
a small panel of putative kinase inhibitors. To explore the
scope of the reaction and provide a set of hinge-binding frag-
ments, we included in the reaction panel keto, boc-protected
aniline, halo, aryl, indanone, pyridyl, pyrazole, azaindole and
quinoline functional groups. To this end, a selection of eight
commercially available, relatively undecorated halides was
Table 1 Optimisation of the reaction conditionsa
Entry Cat1/base1 t2 (h) T (°C) 2ab (%) Cat2/Base2 t2 (h) 4ab (%)
1 Pd(dppf)Cl2/KOAc 18 80 100 Pd(dppf)Cl2/KOAc 1 0
2 Pd(dppf)Cl2/KOAc 18 80 100 Pd(PPh3)4/KOAc 1 0
3 Pd(dppf)Cl2/KOAc 1 120
c 100 Pd(PPh3)4/KOAc 1 0
4 Pd(PPh3)4/KOAc 1 120
c,d 100 Pd(PPh3)4/KOAc 1 0
5 Pd(PPh3)4/KOAc 1 120
c 100 Pd(PPh3)4/Na2CO3(aq) 1 100
6 Pd(PPh3)4/Na2CO3(aq) 1 120
c 0e — — —
7 Pd(PPh3)4/KOAc 45 min 120
c 100 —/Na2CO3(aq) 30 min 100
a Reaction conditions: 1a (1 equiv.), B2(pin)2 (1.2 equiv.), catalyst (10 mol%) and base (3 equiv.) in dioxane (0.5 M) followed by 3a (1 equiv.),
catalyst (10 mol%) and base (2 equiv.). b Conversion by LCMS. cReactions performed in a microwave. d Initially heated to 80 °C over 18 h but after
no product 2a formation was observed, it was heated to 120 °C in a microwave for 1 h. eOnly indanone dimer observed.
Fig. 1 Proposed catalytic cycle.
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Table 2 Scope of reaction to perform basic scaffoldsa
Entry First halide Second halide Product Yieldb (%)





6 1b 3b 53
7 1b 3c 46
8 1b 3d 40
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Entry First halide Second halide Product Yieldb (%)
9 3a 42
10 1c 3b 32
11 1c 3c 62
12 1c 3d 49
13 3a 81
14 1d 3b 45
15 1d 3c 87
16 1d 3d 68
a Reaction conditions: first halide (1 equiv.), B2(pin)2 (1.2 equiv.), Pd(PPh3)4 (10 mol%) and KOAc (3 equiv.) in dioxane (0.5 M) followed by second
halide (1 equiv.) and 2 M Na2CO3 (aq) (2 equiv.).
b Isolated yield.
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chosen: four heteroaromatic rings containing either a hydro-
gen bond acceptor, a hydrogen bond donor or both (3a–d) and
four phenyl moieties (1a–d), to be coupled in combination to
obtain 16 products (4a–p). Within this set is compound 4j,
which is a precursor of the BRAF-selective inhibitor, vemura-
fenib. The isolated yields obtained were good to excellent with
the single exception of 4b (Table 2). Pleasingly, regioselectivity
in the coupling reaction was obtained for 1c (entries 9 to 12)
and 3d (entries 4, 8, 12 and 6), which only reacted at the
bromine and not at the chlorine.
The new protocol was then evaluated for the synthesis of
more complex scaffolds; coupling of halides 1a–d with the
trityl-protected 4-(4-bromopyrazolyl)pyridine 3e provided
GDC-087923 analogues 5a–d in moderate to good yields
(Table 3) with a slightly modified protocol allowing for longer
reaction times.
The 20 compounds synthesised were assessed on a small
panel of kinases using the ProfilerPro® Selectivity Assay Kits
(Caliper Life Sciences, Inc.). The inhibition of 24 kinases was
determined at a compound concentration of 300 μM; of the 20
Table 3 Scope of reaction to form complex scaffoldsa
Entry First halide Second halide Product Yieldb (%)
1 1a 57
2 3e 1b 33
3 3e 1c 49
4 3e 1d 65
a Reaction conditions: first halide (1 equiv.), B2(pin)2 (1.2 equiv.), Pd(PPh3)4 (10 mol%) and KOAc (3 equiv.) in dioxane (0.4 M) followed by second
halide (1 equiv.) and 2 M Na2CO3 (aq) (2 equiv.).
b Isolated yield.
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Table 4 Results of kinase screen using a small panel of kinase inhibitor-like scaffolds
Entry Compound
Kinase % inhibition
AurA RSK1 PRAK Erk1 PKD2 CK1δ CHK1 ABL FYN LYNα CHK2 MET LCK SRC GSK3β Erk2 PKACα INSR MSK1
1 4a 51 41 19 14 38 38 10 41 −2 33 35 16 31 25 56 14 6 24 28
2 4b 76 −2 3 16 6 46 15 37 1 20 41 16 16 20 26 19 −14 61 4
3 4f 60 20 40 8 18 50 13 23 −25 24 35 9 29 8 8 −7 37 46 19
4 4i 61 52 26 7 32 34 0 68 54 63 25 17 61 43 30 10 52 24 42
5 4j 89 91 86 55 87 73 6 87 79 30 43 47 16 79 45 53 46 58 69
6 4k 45 31 22 6 34 70 −9 65 −1 29 18 29 43 19 26 1 22 21 13
7 4l 7 3 −1 0 −35 68 −7 36 18 −7 3 16 11 3 60 3 29 12 13
8 4m 51 30 27 8 13 58 −12 43 27 46 37 28 18 25 14 4 56 26 26
9 4n 99 70 47 62 92 94 80 85 53 76 91 52 63 62 57 66 61 93 43
10 4o 45 34 12 7 16 44 1 95 30 49 18 35 54 23 26 1 37 44 15






















































































































































compounds, 11 showed greater than 50% inhibition of at least
one kinase (Table 4) with compounds 4j, 4n, 4o and 4p
showing greater than 90% inhibition for at least one kinase.
Of these, 4o and 4p have a selective profile, inhibiting just ABL
(entry 10, 4o) or both ABL and CK1 (entry 11, 4p) at the con-
centrations used. There is one commercially available ABL
inhibitor which contains a quinoline moiety, Rebastinib
(DCC-2036), but this has a binding mode in which the quino-
lone does not interact with the hinge region.24
In order to validate hits 4o and 4p, ABL IC50s were deter-
mined (Invitrogen) at a starting compound concentration of
100 μM. Compound 4o inhibits ABL with an IC50 of 8 μM,
corresponding to a high ligand efficiency of 0.45, as shown in
Table 5 and, although it has a higher IC50, a similar ligand
efficiency is observed for 4p with ABL. Conversely, the IC50 of
4p for CK1δ was >300 μM, further highlighting the selectivity
of the scaffold.
Conclusions
In conclusion, a novel, quick and robust microwave-assisted
protocol for the one-pot borylation/Suzuki reaction has been
developed to access a small panel of putative kinase inhibitors
containing a variety of aryl and heteroaryl ring systems. These
scaffolds have been assessed for inhibition of a panel of
kinases, and a ligand efficiency of 0.45 is observed with the
kinase ABL for compound 4o.
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